BRENUS PHARMA AND INSPHERO RECEIVE €1.5 MILLION IN GRANTS FROM THE EUROPEAN EUROSTARS FUND
News 20.01.2023 Paul Bravetti (Brenus CEO) about this collaboration : “Despite advances in therapy, a significant number of cancers remain resistant to treatment because the cancer cells can adapt and become invisible to the immune system, causing the patient to relapse. These cold tumors, which escape the immune cells and become for the...